COMP <GO>
GYRE vs CBIO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Gyre Therapeutics Inc. (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: GYRE 7
— CBIO 1
■ METRIC PARITY
LAST: $4.73 (+3.84%) • MKT CAP: $507.9M
options-implied-move
—
LAST: $12.91 (-4.23%) • MKT CAP: $500.7M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. CBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | CBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | -35.00% | +60.40 | GYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | -13.86% | +13.83 | GYRE | /fcf-yield <GO> |
| Operating Margin | 9.90% | -60.00% | +69.90 | GYRE | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 1.40% | +7.10 | GYRE | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 6.36 | +7.97 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 3/9 | +2.00 | GYRE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.0 | 46.5 | -8.50 | CBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $507.9M | $500.7M | $7.2M | GYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | CBIO REV | GYRE GROSS % | CBIO GROSS % | GYRE FCF | CBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $10.8M | 95.4% | — | -$180.0K | -$72.5M |
| FY 2024 | $105.8M | $112.1M | 96.3% | — | -$6.0M | -$31.1M |
| FY 2023 | $113.5M | $110.0M | — | — | $25.9M | -$34.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
CBIO // BETA —